{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:17:40Z","timestamp":1791447460219,"version":"4.3.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T00:00:00Z","timestamp":1661040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T00:00:00Z","timestamp":1661040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the role of dysmorphic intratumoral vessels as imaging marker for the prediction of high lung shunt fraction (LSF) in patients with hepatocellular carcinoma (HCC). This retrospective study included 403 patients with HCC who underwent a planning arteriography for transarterial radioembolization with administration of <jats:sup>99m<\/jats:sup>Tc-macroaggregated albumin to calculate LSF. The LSF was measured by using planar body scans. Two radiologists evaluated the pre-treatment contrast-enhanced CT findings, including tumor number, size, margin, distribution, tumor burden, portal and hepatic vein invasion, early hepatic vein enhancement, and dysmorphic intratumoral vessels. The logistic regression analysis was performed to determine significant predictors for high LSF\u2009&gt;\u200920%. Using the identified predictors, diagnostic criteria for high LSF were proposed. Among 403 patients, 52 (13%) patients had high LSF\u2009&gt;\u200920%, and dysmorphic tumor vessels were present in 115 (28.5%) patients. Predictors for LSF\u2009&gt;\u200920% were tumor size\u2009&gt;\u200911\u00a0cm, hepatic vein invasion, early hepatic vein enhancement, and dysmorphic intratumoral vessel. If the patient had three or more of the four predictors for LSF\u2009&gt;\u200920% on imaging, the accuracy and specificity for diagnosing LSF\u2009&gt;\u200920% were 88.8% and 96.3% respectively. Dysmorphic intratumoral vessel in HCC is an imaging marker suggesting a high LSF, which may be applicable to treatment modification or patient exclusion for radioembolization with combined interpretation of tumor size and hepatic vein abnormality.<\/jats:p>","DOI":"10.1038\/s41598-022-18697-5","type":"journal-article","created":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T09:02:38Z","timestamp":1661072558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Association of dysmorphic intratumoral vessel with high lung shunt fraction in patients with hepatocellular carcinoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Tae Won","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijin","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,21]]},"reference":[{"key":"18697_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","volume":"33","author":"JR Kallini","year":"2016","unstructured":"Kallini, J. R., Gabr, A., Salem, R. & Lewandowski, R. J. Transarterial radioembolization with Yttrium-90 for the treatment of hepatocellular carcinoma. Adv. Ther. 33, 699\u2013714. https:\/\/doi.org\/10.1007\/s12325-016-0324-7 (2016).","journal-title":"Adv. Ther."},{"key":"18697_CR2","doi-asserted-by":"publisher","unstructured":"Makary, M. S., Khandpur, U., Cloyd, J. M., Mumtaz, K. & Dowell, J. D. Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12071914 (2020).","DOI":"10.3390\/cancers12071914"},{"key":"18697_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3350\/cmh.2017.0004","volume":"23","author":"HC Kim","year":"2017","unstructured":"Kim, H. C. Radioembolization for the treatment of hepatocellular carcinoma. Clin. Mol. Hepatol. 23, 109\u2013114. https:\/\/doi.org\/10.3350\/cmh.2017.0004 (2017).","journal-title":"Clin. Mol. Hepatol."},{"key":"18697_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.20892\/j.issn.2095-3941.2017.0177","volume":"15","author":"Y Yang","year":"2018","unstructured":"Yang, Y. & Si, T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Biol. Med. 15, 299\u2013310. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2017.0177 (2018).","journal-title":"Cancer Biol. Med."},{"key":"18697_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem, R. et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140, 497-507.e492. https:\/\/doi.org\/10.1053\/j.gastro.2010.10.049 (2011).","journal-title":"Gastroenterology"},{"key":"18697_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5582\/bst.2015.01089","volume":"9","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y., Li, Y., Ji, H., Zhao, X. & Lu, H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. Biosci. Trends 9, 289\u2013298. https:\/\/doi.org\/10.5582\/bst.2015.01089 (2015).","journal-title":"Biosci. Trends"},{"key":"18697_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/liv.12637","volume":"35","author":"A El Fouly","year":"2015","unstructured":"El Fouly, A. et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. Liver Int. 35, 627\u2013635. https:\/\/doi.org\/10.1111\/liv.12637 (2015).","journal-title":"Liver Int."},{"key":"18697_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin, E. et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol. Hepatol. 6, 17\u201329. https:\/\/doi.org\/10.1016\/s2468-1253(20)30290-9 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"18697_CR9","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00261-018-1602-4","volume":"43","author":"M Bermo","year":"2018","unstructured":"Bermo, M., Matesan, M. C., Itani, M., Behnia, F. & Vesselle, H. J. Hepatopulmonary shunting on Tc99m-MAA liver mapping: correlation with dynamic cross-sectional imaging and description of different shunting patterns. Abdom. Radiol. (NY) 43, 3001\u20133008. https:\/\/doi.org\/10.1007\/s00261-018-1602-4 (2018).","journal-title":"Abdom. Radiol. (NY)"},{"key":"18697_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0360-3016(95)00039-3","volume":"33","author":"TW Leung","year":"1995","unstructured":"Leung, T. W. et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int. J. Radiat. Oncol. Biol. Phys. 33, 919\u2013924. https:\/\/doi.org\/10.1016\/0360-3016(95)00039-3 (1995).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"18697_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semradonc.2019.08.005","volume":"30","author":"JK Mikell","year":"2020","unstructured":"Mikell, J. K., Dewaraja, Y. K. & Owen, D. Transarterial radioembolization for hepatocellular carcinoma and hepatic metastases: Clinical aspects and dosimetry models. Semin. Radiat. Oncol. 30, 68\u201376. https:\/\/doi.org\/10.1016\/j.semradonc.2019.08.005 (2020).","journal-title":"Semin. Radiat. Oncol."},{"key":"18697_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1148\/radiol.14131969","volume":"271","author":"RC Gaba","year":"2014","unstructured":"Gaba, R. C. et al. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting. Radiology 271, 602\u2013612. https:\/\/doi.org\/10.1148\/radiol.14131969 (2014).","journal-title":"Radiology"},{"key":"18697_CR13","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jvir.2015.07.009","volume":"26","author":"OG Olorunsola","year":"2015","unstructured":"Olorunsola, O. G. et al. Imaging predictors of elevated lung shunt fraction in patients being considered for yttrium-90 radioembolization. J. Vasc. Interv. Radiol. 26, 1472\u20131478. https:\/\/doi.org\/10.1016\/j.jvir.2015.07.009 (2015).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"18697_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1148\/radiol.2017162080","volume":"285","author":"BR Kim","year":"2017","unstructured":"Kim, B. R. et al. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging versus Multidetector CT in the detection of dysplastic nodules and early hepatocellular carcinoma. Radiology 285, 134\u2013146. https:\/\/doi.org\/10.1148\/radiol.2017162080 (2017).","journal-title":"Radiology"},{"key":"18697_CR15","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1259\/bjr\/86767895","volume":"85","author":"JH Lee","year":"2012","unstructured":"Lee, J. H. et al. Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: Comparison with pathological differentiation. Br. J. Radiol. 85, e573-583. https:\/\/doi.org\/10.1259\/bjr\/86767895 (2012).","journal-title":"Br. J. Radiol."},{"key":"18697_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s00261-015-0629-z","volume":"41","author":"YJ Zhao","year":"2016","unstructured":"Zhao, Y. J., Chen, W. X., Wu, D. S., Zhang, W. Y. & Zheng, L. R. Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: Based on the multivariate analysis of contrast-enhanced computed tomography findings. Abdom. Radiol. (NY) 41, 978\u2013989. https:\/\/doi.org\/10.1007\/s00261-015-0629-z (2016).","journal-title":"Abdom. Radiol. (NY)"},{"key":"18697_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s00270-017-1678-1","volume":"40","author":"RN Cavalcante","year":"2017","unstructured":"Cavalcante, R. N. et al. Occurrence of vascular lake phenomenon as a predictor of improved tumor response in HCC patients that underwent DEB-TACE. Cardiovasc. Intervent. Radiol. 40, 1044\u20131051. https:\/\/doi.org\/10.1007\/s00270-017-1678-1 (2017).","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"18697_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s11604-015-0486-2","volume":"33","author":"A Seki","year":"2015","unstructured":"Seki, A., Hori, S. & Shimono, C. Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres. Jpn J. Radiol. 33, 741\u2013748. https:\/\/doi.org\/10.1007\/s11604-015-0486-2 (2015).","journal-title":"Jpn J. Radiol."},{"key":"18697_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1046\/j.1440-1746.2000.02323.x","volume":"15","author":"J Yamanaka","year":"2000","unstructured":"Yamanaka, J. et al. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection. J. Gastroenterol. Hepatol. 15, 1192\u20131198. https:\/\/doi.org\/10.1046\/j.1440-1746.2000.02323.x (2000).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"18697_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/rlu.0000000000000915","volume":"41","author":"M Xing","year":"2016","unstructured":"Xing, M. et al. 90Y radioembolization lung shunt fraction in primary and metastatic liver cancer as a biomarker for survival. Clin. Nucl. Med. 41, 21\u201327. https:\/\/doi.org\/10.1097\/rlu.0000000000000915 (2016).","journal-title":"Clin. Nucl. Med."},{"key":"18697_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.gastro.2013.01.002","volume":"144","author":"V Hernandez-Gea","year":"2013","unstructured":"Hernandez-Gea, V., Toffanin, S., Friedman, S. L. & Llovet, J. M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144, 512\u2013527. https:\/\/doi.org\/10.1053\/j.gastro.2013.01.002 (2013).","journal-title":"Gastroenterology"},{"key":"18697_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.tvir.2019.02.004","volume":"22","author":"BJ Schiro","year":"2019","unstructured":"Schiro, B. J., Amour, E. S., Harnain, C. & Gandhi, R. T. Management of high hepatopulmonary shunts in the setting of Y90 radioembolization. Tech. Vasc. Interv. Radiol. 22, 58\u201362. https:\/\/doi.org\/10.1053\/j.tvir.2019.02.004 (2019).","journal-title":"Tech. Vasc. Interv. Radiol."},{"key":"18697_CR23","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.21873\/invivo.12504","volume":"35","author":"HC Kim","year":"2021","unstructured":"Kim, H. C. et al. Lung shunt reduction for yttrium-90 radioembolization: chemoembolization versus radioembolization. In Vivo 35, 2305\u20132312. https:\/\/doi.org\/10.21873\/invivo.12504 (2021).","journal-title":"In Vivo"},{"key":"18697_CR24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00270-012-0371-7","volume":"35","author":"RC Gaba","year":"2012","unstructured":"Gaba, R. C. & Vanmiddlesworth, K. A. Chemoembolic hepatopulmonary shunt reduction to allow safe yttrium-90 radioembolization lobectomy of hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 35, 1505\u20131511. https:\/\/doi.org\/10.1007\/s00270-012-0371-7 (2012).","journal-title":"Cardiovasc. Intervent. Radiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18697-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18697-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18697-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T07:18:51Z","timestamp":1669360731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18697-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18697"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18697-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,21]]},"assertion":[{"value":"16 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14248"}}